The Nhwa R&D center is one of the most innovative R&D centers in China
It is a national-level R&D facility with provincial-level engineering and technological research capabilities. The center is also the provincial enterprise workstation for academics and a national innovation center for post doctorate students.

The R&D center covers an area of 19000 ㎡. It is equipped with a synthesis lab, preparation lab, pharmacology lab, analysis department, TCM research office and information department. The entire facility is also outfitted with a complete experimental installation and research system.

Today, the Nhwa R&D center focuses on dozens of new drugs with high security intellectual property and undertakes more than a dozen national-level or provincial-level scientific research projects at any given time.

We have obtained 24 authorized patents, among which 4 were authorized by the US, and 2 by the EU. There are 37 patents pending, among which 11 are PCTs.

• Cardiovascular and cerebrovascular diseases
• Anesthesia and pain
• Epilepsy
• Psychiatric disorder
• Neurodegenerative disease

• Neuroscience Victoria Limited (NSV), Australia
• D-Pharm Biotech, Israel
• Mapi Pharm., Israel
• Auckland University, New Zealand
• Others

• We have participated in national level drug R&D projects, and obtained 6 national medals for Significant New Drugs Development.
• The R&D center is the Jiangsu provincial technical center. We have independently developed more than 30 new drugs.
• We pay attention to product R&D, so we have technical cooperation with some pharmaceutical research institutions abroad.
• We utilize advanced R&D equipment sets: synthesis laboratory, analysis room, preparation room, pharmacy room, registration room, information inquiry room, pilot testing room, etc.
• The new R&D center covers an area of 66,666 square meters. It meets GLP standards.